“After the acquisition of Human Med by funds advised by Premium Equity Partners, which was completed in February 2022, we want to build on the previous corporate successes of the Schwerin-team and continue the international growth course in the segment of waterjet-assisted liposuction and regenerative medicine” – says Pieter van Halem, Managing Partner at Premium Equity Partners.
“Dr. Aldinger as the new CEO has extensive industry knowledge in the health care sector, 20 years of sales experience and the necessary management tools to successfully implement business and product strategies,” van Halem added.
Aldinger was appointed to the Management Board by the Supervisory Board of Human Med, and will initially operate as a co-leader with the previous Management Board member Bernd Lindner. After his departure, which is scheduled for the fall, Mr. Lindner will continue to be available to the company in an advisory capacity as needed.
“I am looking forward to the challenges ahead – navigating through unstable economic times worldwide with market developments that are often difficult to predict, requires a high degree of flexibility, creativity and adaptability, which are abundant in every department at Human Med. The team is experienced and dedicated. The current product portfolio is unique and forms the basis for significant growth and exciting projects that will open up new market segments, particularly in regenerative medicine,” comments Aldinger on his new area of responsibility.
“With its patented waterjet-assisted liposuction technology (WAL), Human Med is present in a versatile growth market that is still primarily focused on Europe, but it is also attracting increasing attention from doctors and patients worldwide,” adds Aldinger, who intends to continue this positive development with his team and great vigor. “Human Med has been headquartered in Schwerin from the very beginning – and that will not change in the future,” assures Aldinger.
After completing his doctorate (organic chemistry), the 55-year old Stephan Aldinger, who comes from Mecklenburg-Vorpommern, started his professional career by co-founding the company Teraklin AG, where he was responsible for the development and market launch of a novel therapy for liver support. He gained relevant experience, among other things, at the Swedish company Gambro AB for nine years as Marketing Director and Vice President for Research and Development and for five years at the US group Baxter International as Global Marketing Director – in both companies in the business area of intensive care medicine. For the past 2 years, he has served as Head of Sales and Marketing at Munich-based ADVITOS GmbH.
There have also been changes in the supervisory board: Berthold Hackl replaces the previous chairman, Roger Dullien. “With Mr. Hackl, founder and managing director of the consulting and investment company Sorrento Investment GmbH, Human Med benefits from a personality with a strong entrepreneurial spirit and deep knowledge in the field of life science and medical products,” explains Pieter van Halem. After his academic degree in Molecular Biology at the University of Freiburg, Mr. Hackl pursued a successful international career in various leadership positions, including General Manager Europe at Eurofins Scientific and Board Member of Invendo Medical, which was acquired by AMBU in 2017. Mr. Hackl further has extensive experience as a venture capitalist with a focus on biopharma, orthopedics and women’s health. “Due to his extensive professional expertise, Mr. Hackl is an excellent addition to our supervisory board and the ideal person to support Human Med on its growth path,” concluded van Halem.
About Human Med AG:
The company, headquartered in Schwerin (Mecklenburg-Vorpommern, Germany), is the world’s leading manufacturer of medical devices for waterjet-assisted liposuction (WAL), setting standards in the field of natural, extremely gentle body contouring and has played a pioneering role in the field of aesthetic, reconstructive and regenerative medicine for 20 years. Human Med offers complete systems and accessories for all indications of autologous fat management with proven outstanding results in autologous fat transfer.
Download this press release as PDF.